Today, the SVP of Cel-Sci (CVM), Patricia Prichep, bought shares of CVM for $20K.
Following Patricia Prichep’s last CVM Buy transaction on June 13, 2018, the stock climbed by 8.0%. In addition to Patricia Prichep, 5 other CVM executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.80 and a one-year low of $2.37. The Company has a Price to Book ratio of 55.9430.
The insider sentiment on Cel-Sci has been positive according to 33 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS).
